Kenvue is dealing with another challenge to a top-selling product as it attempts to close its $40 billion acquisition by Kimberly-Clark https://t.co/iaRURQYlVU ...

Key Takeaways KMB posted a seventh straight quarter of volume-plus-mix growth in Q3 2025.Kimberly-Clark has sharply expanded its premium mix in North America and China.KMB balances premium gains with stronger value tiers and selective promotions.Kimberly-Clark Corporation's (KMB) third-quarter 2025 performance suggests that premiumization can continue to support growth ahead of generally modest category trends. Management reported a seventh consecutive quarter of volume-plus-mix-led growth, highlighting the ...

DALLAS, Dec. 12, 2025 /PRNewswire/ -- Kimberly-Clark (NASDAQ: KMB) will issue its fourth quarter and full year 2025 results on Tuesday, January 27, 2026. A press release and supplemental materials will be issued at approximately 6:30 a.m. EST. Kimberly-Clark management will then host a live Q&A session with analysts beginning at 8:00 a.m. EST. The earnings release, supplemental materials, and Kimberly-Clark's Q&A session can be accessed at Kimberly-Clark - Investor Relations. A replay of the webcast will b ...

Core Insights - Kimberly-Clark Corporation (KMB) has seen a significant decline in its stock price, dropping 19.4% over the past three months, which is worse than the Zacks Consumer Products–Staples industry's decline of 9.9% and the Consumer Staples sector's decline of 4.7% [1][5] - The company's performance is impacted by softer global demand, inflation, currency volatility, and increased marketing investments, which are pressuring margins [1][5] - Despite these challenges, Kimberly-Clark is focusing on brand support and innovation to stabilize its performance [1][5] Stock Performance - KMB's stock closed at $103.14, which is 31.4% below its 52-week high of $150.45 reached on March 10, 2025 [2] - The stock is trading below its 50-day and 200-day simple moving averages of $110.31 and $125.33, indicating bearish sentiment [2][3] Comparison with Peers - KMB has underperformed compared to peers such as Procter & Gamble (PG), Albertsons Companies (ACI), and The Clorox Company (CLX), which have seen declines of 11.3%, 8.6%, and 17%, respectively [2][5] - KMB's forward 12-month price-to-earnings (P/E) ratio is 14.60, lower than the industry's average of 17.58, while Procter & Gamble and Clorox have higher P/E ratios of 19.44 and 16.31, respectively [6][8] Financial Pressures - In Q3 2025, KMB's adjusted gross margin decreased by 170 basis points year-over-year due to cost inflation and tariff-related expenses [10] - Currency translation is expected to negatively impact net sales by approximately 100 basis points, with additional declines from divestitures and exits [11][13] - Adjusted earnings per share are projected to be pressured by various factors, including divestitures, higher net interest expenses, and currency translation [14] Strategic Initiatives - Kimberly-Clark is implementing an innovation-led growth strategy and focusing on productivity to navigate current challenges [16][17] - The company is enhancing commercial execution through targeted promotions and digital channel growth [18] - The acquisition of Kenvue is expected to create a $32-billion global health and wellness leader, delivering $2.1 billion in synergies and driving EPS growth [19] Operational Resilience - KMB is addressing currency and tariff volatility through strategic sourcing and supply-chain optimization [20] - The company aims for long-term targets of at least 40% gross margin and an 18-20% operating margin [20] Investment Outlook - While KMB faces significant headwinds, there are signs of stabilization driven by innovation and productivity gains [21] - The upcoming Kenvue acquisition strengthens KMB's long-term strategic position, although integration risks remain [21][22] - Current investors may consider a cautious approach, while those with a higher risk appetite might view the discounted valuation as an opportunity [22][23]

Core Insights - Investors should closely monitor Kimberly-Clark Corporation (KMB) stock due to significant activity in the options market, particularly the Jan 16, 2026 $70 Call, which has high implied volatility [1] Company Overview - Kimberly-Clark is currently rated as Zacks Rank 3 (Hold) in the Consumer Products – Staples industry, which is positioned in the bottom 24% of the Zacks Industry Rank [3] - Over the last 60 days, the Zacks Consensus Estimate for the current quarter has increased from $1.52 per share to $1.55 [3] Options Market Analysis - The high implied volatility in Kimberly-Clark options suggests that traders are anticipating a significant price movement, potentially due to an upcoming event [2][4] - Options traders often seek high implied volatility options to sell premium, aiming to benefit from the decay of options value if the stock does not move as expected [4]

Core Insights - Kimberly-Clark Corporation (KMB) is making significant progress towards its long-term profitability targets, increasing the likelihood of achieving a 40% gross margin sooner than expected [1][11] Financial Performance - KMB's gross margin is anticipated to improve in Q4 2025, driven by productivity initiatives, investment timing, and supply-chain efficiencies [2] - The company has reduced gross tariff costs from $170 million to approximately $100 million, with $50 million already mitigated, contributing to improved profit structure [3] - KMB has experienced seven consecutive quarters of volume-plus-mix growth, reflecting premiumization and innovation-driven growth across categories [4] Strategic Initiatives - The company is focusing on structural measures to reduce volatility in fiber and other inputs, which are essential for long-term margin stability [3] - KMB's premium product mix has significantly increased over time, enhancing pricing power and reinforcing category leadership [4] Market Position - Despite a 22.4% decline in KMB's stock over the past six months, the company is positioned to reach its gross margin milestone ahead of schedule [10][5] - The Zacks Consensus Estimate indicates a year-over-year decline of 12.6% in KMB's 2025 earnings, with a projected growth of 11.3% for 2026 [12] Valuation Metrics - KMB's forward 12-month price-to-sales ratio is 2.02, which is lower than the industry average of 2.08, indicating a relatively lower valuation [14]

Core Insights - Kimberly-Clark Corporation (NASDAQ:KMB) is recognized as one of the 15 Blue Chip Dividend Stocks suitable for building a passive income portfolio [1] - BNP Paribas Exane has lowered its price target for Kimberly-Clark from $127 to $110, maintaining a Neutral rating, citing integration risks related to the planned acquisition of Kenvue expected to close in the second half of 2026 [2] - The company is expanding its manufacturing capabilities in Vietnam, acquiring 1.2 hectares of land to increase production by approximately 40%, with half of its output being exported to 18 different markets [3] - Kimberly-Clark is also enhancing its competitiveness in the digital space by engaging with parenting communities and expanding its e-commerce initiatives [4]

分组1 - Johnson & Johnson (JNJ) spun off its consumer wellness division in 2023, creating a separate company named Kenvue (NYSE: KVUE) to unlock value for the overall enterprise [1] - The spin-off is expected to enhance the focus and operational efficiency of both JNJ and Kenvue, allowing each entity to pursue its strategic goals independently [1] 分组2 - Kenvue is positioned to capitalize on growth opportunities in the consumer wellness market, which may lead to increased shareholder value [1] - The separation of Kenvue from JNJ reflects a broader trend in the healthcare industry where companies are divesting non-core assets to streamline operations and enhance shareholder returns [1]

Group 1 - Johnson & Johnson (JNJ) spun off its consumer wellness division in 2023, creating a separate company named Kenvue (NYSE: KVUE) to unlock value for the overall enterprise [1] - The spin-off is expected to enhance the focus and operational efficiency of both JNJ and Kenvue, allowing each entity to pursue its strategic goals independently [1] Group 2 - Kenvue is positioned to capitalize on growth opportunities in the consumer wellness market, which may lead to increased shareholder value [1] - The separation of Kenvue from JNJ reflects a broader trend in the healthcare industry where companies are divesting non-core segments to streamline operations and enhance shareholder returns [1]

Core Insights - Class Action Attorney Juan Monteverde's firm has successfully recovered millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] Group 1: Repare Therapeutics Inc. - Repare Therapeutics Inc. is being investigated regarding its sale to XenoTherapeutics, Inc. [1] - Upon closing, each Repare shareholder is expected to receive a cash payment of $1.82 per share, along with a non-transferable contingent value right for additional cash payments under certain conditions [1] Group 2: CNB Bank Shares, Inc. - CNB Bank Shares, Inc. is involved in a sale to HBT Financial, Inc. [2] - CNB shareholders will receive either 1.0434 shares of HBT common stock, $27.73 in cash per share, or a combination of both upon completion of the transaction [2] Group 3: Kimberly-Clark Corporation - Kimberly-Clark Corporation is merging with Kenvue Inc. [3] - Post-merger, Kimberly-Clark shareholders are expected to own approximately 54% of the combined company [3] Group 4: Kenvue Inc. - Kenvue Inc. is being sold to Kimberly-Clark Corporation [4] - Kenvue shareholders will receive $3.50 per share in cash plus 0.14625 shares of Kimberly-Clark for each Kenvue share [4]